National Cancer Institution (NCI) Toxicity Criteria



Similar documents
Interpretation of Laboratory Values

Chemotherapy Side Effects Worksheet

Breast Pathway Group FEC 60 (Fluorouracil / Epirubicin / Cyclophosphamide) in Early Breast Cancer in Elderly / Frail

BCCA Protocol Summary for Palliative Treatment of Advanced Pancreatic Neuroendocrine Tumours using SUNItinib (SUTENT )

Essential Shared Care Agreement Drugs for Dementia

St. Luke s MS Center New Patient Questionnaire. Name: Date: Birth date: Right or Left handed? Who is your Primary Doctor?

PATIENT HISTORY FORM

Dallas Neurosurgical and Spine Associates, P.A Patient Health History

SUBSTANCE USE DISORDER SOCIAL DETOXIFICATION SERVICES [ASAM LEVEL III.2-D]

NAME OF THE HOSPITAL: 1. Coronary Balloon Angioplasty: M7F1.1/ Angioplasty with Stent(PTCA with Stent): M7F1.3

Xarelto (rivaroxaban) Prescriber Guide

White, circular, biconvex, uncoated tablets with a score line on one side, plain on the other.

387

Breast Cancer. Breast Cancer Page 1

Breast Pathway Group FEC(100)-Docetaxel: Fluorouracil / Epirubicin / Cyclophosphamide followed by Docetaxel in Early Breast Cancer

Cardiovascular diseases. pathology

NEURO-OPHTHALMIC QUESTIONNAIRE NAME: AGE: DATE OF EXAM: CHART #: (Office Use Only)

SOUTH TAMPA MULTIPLE SCLEROSIS CENTER

PATIENT HEALTH QUESTIONNAIRE Radiation Oncology (Patient Label)

MEDICAL POLICY No R7 DETOXIFICATION I. POLICY/CRITERIA

Program criteria. A social detoxi cation program must provide:

Novartis Gilenya FDO Program Clinical Protocol and Highlights from Prescribing Information (PI)

Lung Pathway Group Nintedanib (Vargatef) in advanced Non-Small Cell Lung Cancer (NSCLC)

Docetaxel + Carboplatin + Trastuzumab (TCH) Adjuvant Breast Cancer

A.P. Chen, MD Director, Developmental Therapeutics Clinic Division of Cancer Treatment and Diagnosis National Cancer Institute

5-Fluorouracil & Radiotherapy for Adjuvant Oesophageal or Gastric Cancer (Modified Macdonald Protocol)

MEDICAL HISTORY AND SCREENING FORM

BCCA Protocol Summary for Palliative Therapy for Metastatic Breast Cancer using Trastuzumab Emtansine (KADCYLA)

This regimen has low emetogenic potential refer to local protocol None required routinely. Baseline results valid for 7 days. Results valid for 72 hrs

Women s Continence and Pelvic Health Center

Safety Information Card for Xarelto Patients

Enhancing the Child s Voice in Clinical Care and Research

ORTHOPAEDIC SPINE PAIN QUESTIONNAIRE

U.S. Department of Health and Human Services Food and Drug Administration Center for Food Safety and Applied Nutrition

Emory Eye Center New Patient Questionnaire

NCD for Lipids Testing

Rivaroxaban: Amber Drug Guidance for the prevention of stroke and systemic embolism in patients with non-valvular AF

LOEWENBERG SCHOOL OF NURSING LOEWENBERG SCHOOL OF NURSING HEALTH EXAMINATION FORM (FORM 003)

Chapter 6 Gastrointestinal Impairment

Emergencies Related to ETHANOL (ETOH) Alcohol

TREATING BIPOLAR DISORDER

Xarelto (rivaroxaban) Prescriber Guide November 2012

NEW PATIENT HISTORY QUESTIONNAIRE. Physician Initials Date PATIENT INFORMATION

PREMEDICATIONS: Agent(s) Dose Route Schedule

Lothian Diabetes Handbook MANAGEMENT OF DIABETIC KETOACIDOSIS

Acute Pancreatitis. Questionnaire. if yes: amount (cigarettes/day): since when (year): Drug consumption: yes / no if yes: type of drug:. amount:.

Laboratory Monitoring of Adult Hospital Patients Receiving Parenteral Nutrition

European Medicines Agency recommends restricting use of trimetazidine-containing medicines

National Stroke Association

Assignment #5. Mineral Deficiency Worksheet. Name Date

6/3/2011. High Prevalence and Incidence. Low back pain is 5 th most common reason for all physician office visits in the U.S.

Xarelto (rivaroxaban) Prescriber Guide

Interventional Spine Care New Patient History and Intake Form

Patient Information Form Pain Management Center at Phoebe

INITIATING ORAL AUBAGIO (teriflunomide) THERAPY

JAMES PETROS, M.D., INC. PHONE: (408) FAX: (408)

All patients presenting to the Emergency Department with symptoms suggestive of

THE BASICS. Community Based Medically Assisted Alcohol Withdrawal. World Health Organisation The Issues 5/18/2011. RCGP Conference May 2011

SMU Drug Free Schools and Campuses Information for New Employees

Core Safety Profile. Pharmaceutical form(s)/strength: 50mg tablets IE/H/PSUR/0028/002 Date of FAR:

North Carolina Orthopaedic Clinic Patient Registration Form

Diuretics: You may get diuretic medicine to help decrease swelling in your brain. This may help your brain get better blood flow.

Recognition and Treatment of Depression in Parkinson s Disease

Pulmonary Associates of Richmond

Things You Should Know About Adverse Event Report Data

External Radiation Side Effects Worksheet

Atrial fibrillation: medicines to help reduce your risk of a stroke what are the options?

Application For Admission To The Non-Surgical Spinal Decompression Program At The Spinal Decompression Center of Long Beach

ALCOHOL WITHDRAWAL SYNDROME

PATIENT REGISTRATION

DATA SHEET. This product is may not be interchangeable with other products containing this ingredient in the New Zealand Market.

Full name DOB Age Address Phone numbers (H) (W) (C) Emergency contact Phone

Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM FEC-T. Patient s first names. Date of birth.

MANAGEMENT OF COMMON SIDE EFFECTS of INH (Isoniazid), RIF (Rifampin), PZA (Pyrazinamide), and EMB (Ethambutol)

Multiple Sclerosis (MS)

LEMTRADA REMS Education Program for Prescribers

Adjunctive psychosocial intervention. Conditions requiring dose reduction. Immediate, peak plasma concentration is reached within 1 hour.

The early symptoms of acute salicylism are the triad of gastrointestinal distress, tinnitus or altered hearing, and hyperventilation.

Alcohol and nicotine are widely abused substances and are often used together One study showed that 15% of patients visiting a primary care practice

Steps to getting a diagnosis: Finding out if it s Alzheimer s Disease.

VAERS_ID SYMPTOM1 SYMPTOMVERSION1 SYMPTOM2 SYMPTOMVERSION2 SYMPTOM3 SYMPTOMVERSION3 SYMPTOM4 SYMPTOMVERSION4 SYMPTOM5 SYMPTOMVERSION

Preoperative Laboratory and Diagnostic Studies

Nursing Process Focus Patients Receiving Morphine Potential Nursing Diagnoses

NEW PATIENT CLINICAL INFORMATION FORM. Booth Gardner Parkinson s Care & Movement Disorders Center Evergreen Neuroscience Institute

Dehydration & Overhydration. Waseem Jerjes

patient group direction

Roswell Ear, Nose, Throat, & Allergy 342 W. Sherrill Lane Suite A, Roswell, New Mexico (575) Fax: (575)

STAGES OF SHOCK. IRREVERSIBLE SHOCK Heart deteriorates until it can no longer pump and death occurs.

PATIENT CONSENT TO PROCEDURE - ROUX-EN-Y GASTRIC BYPASS

(Please fill this out to the best of your ability) Baker Eye Institute Conway, Arkansas NAME: Today s Date:

EXHIBIT H SETTLEMENT ELIGIBILITY CRITERIA. a) pharmacy records reflecting the dispensing of Bextra and/or Celebrex to the Class Member; or

HOW TO ADVOCATE FOR YOURSELF. Presented by: Melissa Sammons Hughes MD FAAP Lupus Foundation of America, GA Chapter Board of Directors, Former Member

1MFBTF GJMM PVU GPSNT BOE GBY 'PSNT XJMM CF TJHOFE BU ZPVS BQQPJOUNFOU

HUMULIN R REGULAR INSULIN HUMAN INJECTION, USP (rdna ORIGIN) 100 UNITS PER ML (U-100)

Guide to Critical Illness Definitions For guidance purposes only

Surgery Health Survey

Transcription:

National Cancer Institution (NCI) Toxicity Criteria Toxicity Grade 0 1 2 3 4 Blood/Bone Marrow WBC?4.0 3.0-3.9 2.0-2.9 1.0-1.9 <1.0 PLT WNL 75.0 - normal 50.0-74.9 25.0-49.9 <25.0 Hgb WNL 10.0 - normal 8.0-10.0 6.5-7.9 <6.5 Granulocytes/ Bands?2.0 1.5-1.9 1.0-1.4 0.5-0.9 <0.5 Lymphocytes?2.0 1.5-1.9 1.0-1.4 0.5-0.9 <0.5 Haemorrhage None mild, no transfusion gross, 1-2 units gross, 3-4 units massive, >4 units (clinical) transfusion per transfusion per transfusion per episode episode episode Infection None mild moderate severe life-threatening Gastrointestinal Nausea able to eat reasonable intake intake significantly decreased but can eat Vomiting 1 episode in 24 hrs 2-5 episodes in 24 hrs no significant intake --- 6-10 episodes in 24 >10 episodes in 24 hrs, hrs or requiring parenteral support Diarrhoea increase of 2-3 increase of 4-6 increase of 7-9 increase of?10 stools/day over stools/day, or stools/day, or stools/day or grossly pre-rx nocturnal stools, or incontinence, or bloody diarrhoea, or moderate cramping severe cramping need for parenteral support Stomatitis painless ulcers, painful erythema, painful erythema, requires parenteral or erythema, or mild oedema, or ulcers, oedema, or ulcers, enteral support soreness but can eat and cannot eat NCI Toxicity Criteria Page 1 of 6

Liver Bilirubin WNL --- ULN-1.5 x ULN >1.5-3.0 x ULN >3.0 x ULN Transaminase (SGOT, SGPT) WNL >ULN-2.5 X ULN >2.5-5.0 X ULN >5.0-20.0 X ULN >20.0 x ULN Alkaline Phosphatase or 5'nucleotidase WNL >ULN-2.5 X ULN >2.5-5.0 X ULN >5.0-20.0 x ULN >20.0 x ULN Liver -- (clinical) no from baseline --- --- precoma hepatic coma Kidney, Bladder Creatinine WNL >ULN-1.5 x ULN >1.5-3.0 x ULN >3.0-6.0 x ULN >6.0 x ULN Proteinuria no 1 + or < 0.3 g% 2-3 + or 0.3-1.0 4 + or > 1.0 g% nephrotic syndrome or < 3 g/l g% or 3-10 g/l or > 10 g/l Haematuria negative micro only gross, no clots gross + clots requires transfusion Alopecia no loss mild hair loss pronounced or total loss --- --- Pulmonary with dyspnoea on dysp noea at normal dyspnoea at rest abnormality in PFTs significant exertion level of activity NCI Toxicty Criteria Page 2 of 6

Heart Cardiac recurrent or requires treatment requires monitoring; dysrhythmias transient, requiring persistent, no or hypotension, no therapy therapy required or ventricular tachycardia, or fibrillation Cardiac function normal mild CHF, Severe or refractory decline of resting decline of resting responsive to CHF ejection fraction by ejection fraction by therapy less than 20% of more than 20% of baseline value baseline value Cardiac -- non-specific T-wave angina without acute myocardial ischaemia flattening ST and T - wave evidence of infarction s suggesting infarction ischaemia Cardiac -- asymptomatic pericarditis (rub, symptomatic tamponade; drainage pericardial effusion, no chest pain, ECG effusion; drainage urgently required intervention required s) required Blood Pressure Hypertension recurrent or requires therapy hypertensive crisis transient increase by persistent increase greater than 20 mm by greater than 20 Hg (D) or to mm Hg (D) or to >150/100 if >150/100 if previously WNL. previously WNL. No treatment No treatment required required Hypotension s requiring no requires fluid requires therapy and requires therapy and therapy (including replacement or other hospitalisation; hospitalisation for >48 transient orthostatic therapy but not resolves within 48 hrs after stopping the hypotension) hospitalisation hrs of stopping the agent agent NCI Toxicty Criteria Page 3 of 6

Neurological sensory mild paresthesias, loss of deep tendon reflexes mild or moderate objective sensory loss; moderate severe objective sensory loss or paresthesias that --- paresthesias interfere with function subjective weakness; mild objective objective weakness paralysis motor no objective weakness without with impairment of findings significant function impairment of function cortical mild somnolence or moderate severe somnolence, coma, seizures, toxic agitation somnolence or agitation, confusion, psychosis agitation disorientation, or hallucinations slight intention tremor, locomotor ataxia cerebellar necrosis cerebellar incoordination, dysmetria, slurred dysdiadochokinesia speech, nystagmus mood no mild anxiety or moderate anxiety or severe anxiety or suicidal ideation depression depression depression mild moderate or severe unrelenting and --- headache but transient severe constipation mild moderate severe ileus >96 hrs hearing tinnitus hearing loss deafness not hearing loss on interfering with correctable audiometry only function but correctable with hearing aid vision --- --- symptomatic blindness subtotal loss of vision NCI Toxicty Criteria Page 4 of 6

Skin scattered macular or scattered macular or generalized exfoliative dermatitis papular eruption or papular eruption or symptomatic or ulcerating dermatitis erythema that is erythema with macular, papular, or asymptomatic pruritus or other vesicular eruption associated symptoms Allergy transient rash, drug urticaria, drug fever serum sickness, anaphylaxis fever <38 C, 100.4? F =38 C, 100.4?F mild bronchospasm bronchospasm, req parenteral meds Fever in absence of infection 37.1-38.0 C 38.1-40.0 C >40.0 C for less than 24 hrs >40.0 C (104.0 F) for more than 24 hrs or fever accompanied by hypotension Local pain pain and swelling, with inflammation or phlebitis ulceration plastic surgery indicated Weight gain/loss <5.0% 5.0-9.9% 10.0-19.9%?20.0% --- Metabolic Hyperglycaemia <116 116-160 161-250 251-500 >500 or ketoacidosis Hypoglycaemia >64 55-64 40-54 30-39 <30 Amylase WNL <1.5 x N 1.5-2.0 x N 2.1-5.0 x N >5.1 x N Hypercalcaemia <10.6 10.6-11.5 11.6-12.5 12.6-13.5?13.5 Hypocalcaemia >8.4 8.4-7.8 7.7-7.0 6.9-6.1?6.0 Hypomagnesaemi >1.4 1.4-1.2 1.1-0.9 0.8-0.6?0.5 a NCI Toxicty Criteria Page 5 of 6

Coagulation Fibrinogen WNL 0.99-0.75 x N 0.74-0.50 x N 0.49-0.25 x N?0.24 x N Prothrombin time WNL 1.01-1.25 x N 1.26-1.50 x N 1.51-2.00 x N >2.00 x N Partial thromboplastin time WNL 1.01-1.66 x N 1.67-2.33 x N 2.34-3.00 x N >3.00 x N NCI Toxicty Criteria Page 6 of 6